See All Slides - tctmd.com

Slides

Presentation TCT 2013

How Important Is Paravalvular Leak After TAVR and Will This Limit Its Penetration?

Presenter: Samir Kapadia

October 29, 2013

Presentation

SALUS I Trial Update

Presenter: E. Murat Tuzcu

October 29, 2013

Presentation TCT 2013

Synthesis of the Current US and EU Guidelines for Management of SIHD (Similarities and Differences)

Presenter: Kevin Beatt

October 29, 2013

Presentation TCT 2013

TCT-60. Clinical and Procedural Outcomes of Renal Artery Denervation In Real World Patients with Hypertension: An Update From the Global SYMPLICITY Registry

Presenter: Felix Mahfoud

October 29, 2013

Presentation TCT 2013

Update on the Global Registry of Degenerative Bioprosthetic Valves

Presenter: Danny Dvir

October 29, 2013

Presentation TCT 2013

CLI and PVD: Where Are We and Where Are the patients?

Presenter: Amit Patel

October 29, 2013

Presentation TCT 2013

PCI of an Invisible RCA Ostial CTO Assisted By CT

Presenter: Jin-Ho Choi

October 29, 2013

Presentation TCT 2013

TCT-66. Risk stratification after endovascular treatment in claudicant patients with Iliofemoral artery disease

Presenter: Miura Takashi

October 29, 2013

Presentation

Perspectives in Individualized Antiplatelet Therapy: Comorbidities and Characteristics

Presenter: Deepak Bhatt

October 29, 2013

Presentation TCT 2013

How Would I Treat This Case?(2)

Presenter: Alejandro Cherro

October 29, 2013

Advertisement

Slides

How Important Is Paravalvular Leak After TAVR and Will This Limit Its Penetration?

SALUS I Trial Update

Synthesis of the Current US and EU Guidelines for Management of SIHD (Similarities and Differences)

TCT-60. Clinical and Procedural Outcomes of Renal Artery Denervation In Real World Patients with Hypertension: An Update From the Global SYMPLICITY Registry

Update on the Global Registry of Degenerative Bioprosthetic Valves

CLI and PVD: Where Are We and Where Are the patients?

PCI of an Invisible RCA Ostial CTO Assisted By CT

TCT-66. Risk stratification after endovascular treatment in claudicant patients with Iliofemoral artery disease

Perspectives in Individualized Antiplatelet Therapy: Comorbidities and Characteristics

How Would I Treat This Case?(2)

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content